NKTR vs PFE · rev $21.0M vs P/E 20, rev $15.03B
Nektar Therapeutics (NKTR) versus Pfizer Inc (PFE) — a side-by-side from cached financials, not a winner call.
Nektar Therapeutics (NKTR) is a biotechnology company listed on US.
Pfizer Inc (PFE) is a drug manufacturers - general company listed on NYSE. It is led by Albert Bourla.
Latest reported NKTR revenue for 2026-06-30 was $21.0M. Net income was -$85.5M. Revenue was up 93.3% from 2026-03-31 to 2026-06-30. NKTR currently screens at market cap $307.2M.
Latest reported PFE revenue for 2026-06-28 was $15.03B. Net income was -$248.0M. Revenue was up 4.0% from 2026-03-29 to 2026-06-28. PFE currently screens at market cap $147.73B and trailing P/E 19.8.
NKTR currently screens at market cap $307.2M. PFE currently screens at market cap $147.73B and trailing P/E 19.8.
Not investment advice. Open the NKTR and PFE stock pages for the full models.
Not investment advice.